Table 4. Susceptibilities.
| Community onset (n = 143)* | ||||||||
|---|---|---|---|---|---|---|---|---|
| Overall | Community acquired (n = 83) | Healthcare associated (n = 57) | Hospital acquired (n = 58) | |||||
| Drug | n | % Susceptible | n | % Susceptible | n | % Susceptible | n | % Susceptible |
| Linezolid | 200 | 100% | 83 | 100% | 57 | 100% | 57 | 100% |
| Vancomycin | 201 | 100% | 83 | 100% | 57 | 100% | 58 | 100% |
| Quinolone | 162 | 92% | 66 | 92% | 46 | 89% | 47 | 94% |
| Oxacillin | 196 | 90% | 79 | 94% | 56 | 86% | 58 | 90% |
| Tetracycline | 181 | 87% | 73 | 86% | 52 | 87% | 53 | 87% |
| Clindamycin1 | 200 | 85% | 83 | 90% | 56 | 82% | 58 | 79% |
| Erythromycin | 201 | 82% | 83 | 87% | 57 | 77% | 58 | 79% |
| TMP/SMX | 157 | 64% | 62 | 65% | 45 | 64% | 49 | 63% |
| Penicillin | 197 | 12% | 80 | 10% | 56 | 18% | 58 | 9% |
153% (10/19) of the ORSA isolates were susceptible to clindamycin
*Of the 143 community onset cases, 3 were not classified into healthcare associated or community acquired due to inadequate documentation in the medical record.